India Globalization Capital, Inc. (IGC)

igcIndia Globalization Capital, Inc operates in several locations around the world to acquire, incubate, finance, and grow companies in various industries. Through its subsidiaries, it has businesses in India, Inner Mongolia, China, Hong Kong, and the United States. Its business lines include iron ore processing, electronic components trading, clean energy, equipment leasing, and vertical farming, and it has entered the marijuana industry as well.

The company’s foray into the legal cannabis industry involves its vertical farming projects in the US. Currently, it is planning to build indoor vertical farms designed to produce organic green vegetables, and eventually, legal marijuana. Also part of the company’s strategy are creating a portfolio of cannabis and hemp-based patents, developing FDA-approved drugs based on cannabinoids, and establishing a cannabis R&D laboratory.

More recently, the multi-national company acquired Midtown Partners & Co, LLC, a New York-based licensed broker-dealer, to expand its marijuana strategy. With Midtown as its subsidiary, IGC will offer capital-raising platforms and broker-dealer services to cannabis businesses. One of the major platforms it plans to build is a crowdfunding site for small to midsize enterprises. Other services will include investment banking and equity research.

The legal marijuana industry is only one of the areas where IGC intends to expand. To minimize its dependence on its iron ore business, its diversification strategy aims for growth in clean technology, solar energy, and specialty pharmaceuticals as well.

India Globalization Capital was incorporated in Maryland in 2005. It now trades in the NYSE MKT with the symbol IGC, and a market cap of USD 8.69 M.

Among the top management executives in the company are Ram Mukunda, CEO, President, and Director; Daniel Ngai, Principal Financial and Accounting Officer; and Belur Ram Kishan, Sunny Tsang, and Amit Dutta, Managing Directors.


Yahoo! Finance: IGC News

Latest Financial News for IGC

IGC Announces IRB Approval of its IGC-AD1 for a Phase-2 study

India Globalization Capital, Inc. (IGC) announced today that the Institutional Review Board (“IRB”), in Puerto Rico, approved its protocol for a double-blind, placebo-controlled, efficacy, safety and tolerability study of its proprietary formulation IGC-AD1 on behavior and functionality in subjects with dementia from Alzheimer’s disease. “With this important approval, our Company can implement a 50-person double-blind placebo-controlled trial that we hope begins to prove the efficacy of micro-doses of cannabis in combination with other natural compounds on the behavior of patients suffering from Alzheimer’s. We expect to measure improvements in neuropsychiatric symptoms (“NPI”) such as delusions, agitation/aggression, dysphoria, anxiety, sleep disorder, disinhibition, irritability, apathy and eating abnormalities, among others,” stated Ram Mukunda, CEO.

IGC Reports Financial Results for the Quarter Ended June 30, 2019

Fiscal 2020 First Quarter Sees Multiple Steps

Lifshitz & Miller LLP Announces Investigation of Amneal Pharmaceuticals, Inc., CareDx, Inc., Casa Systems, Inc., India Globalization Capital, Inc., Just Energy Group Inc., LegacyTexas Financial Group, Inc., Maxar Technologies Inc., and Unum Group

NEW YORK , July 26, 2019 /PRNewswire/ --   Amneal Pharmaceuticals, Inc. (AMRX) Lifshitz & Miller  announces investigation into possible securities laws violations in connection with allegations that Amneal ...

Money flows in 17 popular marijuana stocks show fewer ‘short squeezes’

Prior low-level convictions for marijuana possession will be pardoned. Amid this news, one would expect marijuana stocks to run higher, but that’s not happening. Just like a doctor does X-rays to see what is going on inside the human body, investors can do an X-ray of marijuana stocks to figure out what is really going on.

Marijuana Penny Stocks: Where Risk Meets Sin

Marijuana producers and users, working in a market that's still illegal in many states, are a risky but promising bet for investors.